Clinical trials: Resectable
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
Pancreatic Ductal Adenocarcinoma
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor…
- Trial name
- NEOiPANC (NCT03979066)
- Testing
- Atezolizumab, PEGPH20
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gulam Manji
Resectable Esophageal Cancer, GastroEsophageal Cancer
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer.
- Trial name
- NCT03490292
- Testing
- Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma.
- Trial name
- NCT03217266
- Testing
- Navtemadlin, Radiation Therapy, Surgical Procedure
- Where
- 53 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma
This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC.
- Trial name
- NCT05908786
- Testing
- Atezolizumab, Bevacizumab, Tiragolumab
- Where
- 14 sites in United States, Austria and 4 more
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
This phase II trial studies how well trifluridine/tipiracil and oxaliplatin work as the first line of treatment (induction) in treating patients with esophageal or gastroesophageal junction adenocarcinoma that can be removed by…
- Conditions
- Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04097028
- Testing
- Trifluridine and Tipiracil Hydrochloride, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has…
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01959672
- Testing
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Pancreas, Adenocarcinoma
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma
This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and…
- Trial name
- LAPC-BC-819 (NCT01413087)
- Testing
- Biological/Vaccine: BC-819
- Where
- 9 sites in United States, Israel
- Volunteers
- 12 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Non Small Cell Lung Cancer
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with…
- Trial name
- NCT05577702
- Testing
- Tislelizumab, Ociperlimab, Alcestobart
- Where
- 14 sites in China
- Volunteers
- 121 people
- Sponsor
- BeiGene
Head and Neck Cancer, Precancerous Condition
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01084083
- Testing
- cetuximab, intensity-modulated radiation therapy (IMRT), Paclitaxel
- Where
- 121 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery.
- Conditions
- Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer
- Trial name
- NCT03433469
- Testing
- Osimertinib, Therapeutic Conventional Surgery
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of California, San Francisco
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00861705
- Testing
- Bevacizumab, Carboplatin, Cyclophosphamide
- Where
- 448 sites in United States
- Volunteers
- 454 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib).
- Trial name
- NCT01431794
- Testing
- LDE225-600mg, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Solid Tumor
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
Baseline levels of PAR-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of PAR-4 would constitute an important therapeutic advance.The apoptosis…
- Trial name
- NCT02232243
- Testing
- Hydroxychloroquine, 200mg twice dailiy, Hydroxychloroquine, 400mg twice daily
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Peng Wang, MD PhD